Literature DB >> 3980333

The influence of dosing schedules and cerebrospinal fluid bactericidal activity on the therapy of bacterial meningitis.

W M Scheld, M G Tauber, O Zak, M A Sande.   

Abstract

Bacterial meningitis represents an infection in an area of impaired host defence. Optimal therapy of meningitis requires attaining bactericidal activity within cerebrospinal fluid (CSF). Studies in experimental animal models of meningitis suggest that maximal rates of bacterial killing in vivo and optimal cure rates are achieved when CSF antibiotic concentrations exceed the MBC of the test strain by greater than or equal to ten-fold. The results of clinical trials support this conclusion. In addition, a variable post-antibiotic effect occurs in-vivo after short periods of exposure to antimicrobial activity, thus maintaining therapeutic efficacy with intermittent dosage regimens. These basic principles of therapy are outlined in this review and serve as a basis for rational treatment regimens. For most antibiotics, the optimal dose, dosage interval, and duration of therapy for bacterial meningitis remain to be established.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3980333     DOI: 10.1093/jac/15.suppl_a.303

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

Review 1.  Animal models as predictors of the safety and efficacy of antibiotics.

Authors:  O Zak; T O'Reilly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

Review 2.  Cerebrospinal fluid diversion devices and infection. A comprehensive review.

Authors:  R Gutiérrez-González; G R Boto; A Pérez-Zamarrón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-30       Impact factor: 3.267

3.  Once-daily gentamicin therapy for experimental Escherichia coli meningitis.

Authors:  A Ahmed; M M París; M Trujillo; S M Hickey; L Wubbel; S L Shelton; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.